Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687312 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| SCHEMBL4696319 | 0.95 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| SCHEMBL4766363 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| SCHEMBL605459 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| SCHEMBL239923 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| Hydrochloric Acid SCHEMBL697480 | 0.88 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| Hydrochloric Acid SCHEMBL697481 | 0.88 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2BKDM1A | |
| SCHEMBL20282266 | 0.87 | GRIN2B (0.56) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL4697491 | 0.87 | GRIN2B (0.56) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL20267493 | 0.87 | GRIN2B (0.56) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067628-A1 | A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-04-27 | — | — | WO | disclosed |
| EP-2022852-B1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE AMINE COMPOUND, RECOMBINANT VECTOR, AND TRANSFORMANT CARRYING THE VECTOR | KANEKA CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-2123769-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2015-06-18 | — | — | US | disclosed |
| CN-103865964-A | Method for synthesizing (R)-3-amino-piperidine by adopting transaminase method | SHANGHAI PUYI CHEMICAL CO LTD | 2014-06-18 | — | — | CN | disclosed |
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | KANEKA CORPORATION (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338142-B2 | Method for producing optically active 3-aminopiperidine or salt thereof | KANEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-8168412-B2 | Method for producing optically-active amine compound, recombinant vector, and transformant containing the vector | KANEKA CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-1307457-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010172-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2002-02-07 | — | — | WO | disclosed |
| US-6214846-B1 | TREATING INFLAMMATION, MIGRAINE, EMESIS, POSTHERPETIC NEURALGIA, DEPRESSION OR ANXIETY | MERCK SHARP & DOHME LIMITED | 2001-04-10 | — | — | US | disclosed |
| US-6096766-A | 3-benzylaminopiperidines as tachykinin receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| US-6096766-A | 3-benzylaminopiperidines as tachykinin receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0287696-B1 | ISOQUINOLINE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
| EP-0287696-A1 | Isoquinoline derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4500452-A | NOT SUBJECT TO ENZYME DEACTIVATION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-02-19 | — | — | US | disclosed |
| US-4472304-A | CARCINOSTATIC | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079525-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | SLC6A2 764/4885SLC6A4 844/4885SLC6A3 691/4885 |
| US-20150166481-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF | NPEPPS, APEH, DNPEP | SLC6A2 764/4885SLC6A4 844/4885SLC6A3 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.